Clinical Trials on Nefrotisk+syndrom

Total 34060 results

Instituto de Investigación Biomédica de Salamanca
Carlos III Health Institute

Recruiting

Unified platforM for a Better integRal Evaluation of MyeLodyspLastic Syndromes in SpAin-Strategy for Unraveling Personalized genoMic Medicine in Public heAlth System (UMBRELLA-SUMMA) (UMBRELLA-SUMMA)

Myelodysplastic Syndromes

Spain
Kind Pharmaceuticals LLC

Not yet recruiting

A Study of Efficacy and Safety of AND017 in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes
National Cancer Institute (NCI)

Recruiting

Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
Syros Pharmaceuticals

Recruiting

Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

Myelodysplastic Syndromes

United States, Spain, Belgium, Israel, France, United Kingdom, Austria, Czechia, Italy, Poland, Canada, Hungary, Germany
Gruppo Italiano Malattie EMatologiche dell'Adulto

Recruiting

Molecular Mechanisms of Disease Relapse After Allogenic Stem Cell Transplantation in MDS Patients

Myelodysplastic Syndromes

Italy
Syntrix Biosystems, Inc.
Johns Hopkins University; Mayo Clinic; National Heart, Lung, and Blood Institute... and other collaborators

Recruiting

Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome

Myelodysplastic Syndromes

United States
Centre Hospitalier Universitaire, Amiens

Recruiting

Immunophenotyping of Blood Cells in the Diagnosis Work-up of Myelodysplastic Syndromes (MODIFY)

Myelodysplastic Syndromes

France
The University of Hong Kong

Recruiting

Clinical and Genomic Registry of MDS in Asia

Myelodysplastic Syndromes

Hong Kong
Washington University School of Medicine
Sunesis Pharmaceuticals

Completed

Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
Sclnow Biotechnology Co., Ltd.

Suspended

Research for Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-MDS) in the Treatment of Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes

China
NYU Langone Health
Perlmutter Cancer Center

Completed

A Phase Ib Study Evaluating the Safety and Tolerability of Vitamin C in Patients With Intermediate or High Risk Myelodysplastic Syndrome With TET2 Mutations

Myelodysplastic Syndromes

United States
Gilead Sciences

Terminated

Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) (ENHANCE)

Myelodysplastic Syndromes

United States, Spain, Belgium, Australia, France, Hong Kong, Hungary, Finland, New Zealand, Germany, Netherlands, United Kingdom, Italy, Switzerland, Portugal, Canada, Austria, Czechia, Norway, Poland, Turkey
Celgene

Completed

Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States, United Kingdom, Australia, Poland, Spain, Belgium, Italy, Germany, France, Canada
Sohag University

Completed

Clinical and Laboratory Parameters of Myelodysplastic Syndromes at Upper Egypt

Myelodysplastic Syndromes

Egypt
National Cancer Institute (NCI)

Active, not recruiting

BMS-986253 in Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
CrystalGenomics, Inc.

Active, not recruiting

Phase 1/2 Study of CG200745 PPA for Myelodysplastic Syndrome

Myelodysplastic Syndrome

Korea, Republic of
Geron Corporation

Available

Expanded Access for Treatment With Imetelstat

Myelodysplastic Syndromes
Innovent Biologics (Suzhou) Co. Ltd.

Suspended

Safety and Efficacy of IBI188 With Azacitidine in Subjects With Newly Diagnosed Higher Risk MDS

Myelodysplastic Syndromes

China
Karyopharm Therapeutics Inc

Withdrawn

Efficacy & Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome Patients (SIER)

Myelodysplastic Syndrome
SymBio Pharmaceuticals

Completed

Study of SyB C-1101 in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome

Japan
Takeda

No longer available

Expanded Access Program With Pevonedistat (Given With Azacitidine) for Adults With Higher-risk Myelodysplastic Syndromes

Myelodysplastic Syndromes
Istituto Clinico Humanitas

Active, not recruiting

GENOMED4ALL: Improving MDS Classification and Prognosis by AI

Myelodysplastic Syndromes

Italy
Celgene

Completed

Non-interventional Study of Lenalidomide in the Clinical Routine Treatment of TD Patients With IPSS Low or Int-1 MDS and Isolated Del(5q) (PASS MDS del5q)

Myelodysplastic Syndrome

Spain, United Kingdom, Denmark, Germany, France, Greece, Italy, Sweden, Belgium, United States, Luxembourg, Norway
University Hospital, Bordeaux

Active, not recruiting

Cohort Study Assessing the Treatment Strategy for High-Risk Myelodysplastic Syndromes in Patients Under 70 (COMYRE)

Myelodysplastic Syndromes

France
Gustavo Rivero
Baylor College of Medicine

Terminated

Sertraline in Treatment of Low-Risk Myelodysplastic Syndrome (SS1)

Myelodysplastic Syndromes

United States
Assiut University

Completed

Mean Platelet Volume and Its Relation to Risk Stratification of Myelodysplastic Syndromes

Myelodysplastic Syndromes
Groupe Francophone des Myelodysplasies

Completed

Intensified Azacitidine in High Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

France
MedPacto, Inc.

Completed

Dose Escalation and Proof-of-Concept Studies of Vactosertib (TEW-7197) Monotherapy in Patients With MDS

Myelodysplastic Syndromes

United States
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

Observational Evaluation of Infective Risk in Myelodysplastic Syndrome Patients

Myelodysplastic Syndrome

Italy
Genzyme, a Sanofi Company

Completed

Antithymocyte Globulin Compared With Supportive Care in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes

United States, Canada
Array Biopharma, now a wholly owned subsidiary...

Completed

A Study of ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
Kura Oncology, Inc.

Terminated

Tipifarnib in Subjects With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
Celgene

Completed

Study of Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes

Taiwan
University of Cincinnati
Genentech, Inc.

Withdrawn

The Role of Erlotinib an Epidermal Growth Factor Receptor (EGFR) Inhibitor in the Treatment of Myelodysplastic Syndrome

Myelodysplastic Syndrome

United States
Istituto Clinico Humanitas

Unknown

An European Platform for Translational Research in Myelodysplastic Syndromes

Myelodysplastic Syndromes

Italy, Germany, France, Spain
Weill Medical College of Cornell University
Celgene

Terminated

Efficacy and Safety of Lenalidomide in Combination With Cyclosporine A in Patients With Myelodysplastic Syndromes

Myelodysplastic Syndrome

United States
Celgene

Completed

A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care

Myelodysplastic Syndromes

United States, France, Spain, Australia, Czechia, United Kingdom, Italy, Germany, Greece, Poland, Russian Federation, Bulgaria, Sweden, Netherlands, Hungary
Eli Lilly and Company

Completed

A Study of Galunisertib in Participants With Myelodysplastic Syndromes

Myelodysplastic Syndromes

Germany, Spain, Italy
Groupe Francophone des Myelodysplasies
Merck Sharp & Dohme LLC

Terminated

Addition of Vorinostat to Azacitidine in Higher Risk MDS a Phase II add-on Study in Patients With Azacitidine Failure (GFM-AZA-VOR)

Myelodysplastic Syndrome

France
St. Petersburg State Pavlov Medical University

Terminated

Nivolumab With Chemotherapy in Refractory MDS

Myelodysplastic Syndromes

Russian Federation
National Heart, Lung, and Blood Institute (NHLBI)

Completed

A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes

United States
M.D. Anderson Cancer Center
Novartis Pharmaceuticals

Terminated

Study of LBH589 for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

United States
Grupo Español de Síndromes Mielodisplásicos

Completed

Spanish Registry of Erythropoietic Stimulating Agents Study (SPRESAS)

Myelodysplastic Syndrome
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS

Myelodysplastic Syndromes

Italy
Weill Medical College of Cornell University
CTI BioPharma

Completed

Study of Clinical Efficacy and Safety of Tosedostat in MDS (IST-CTI-MDS)

Myelodysplastic Syndrome

United States
Onconova Therapeutics, Inc.

Withdrawn

Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

United States
University of Florida
Teva Pharmaceutical Industries, Ltd.

Withdrawn

A Clinical Trial of Omacetaxine, Azacitidine, and Growth-Colony Stimulating Factor (G-CSF) for Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes

United States
Shandong University

Unknown

Efficacy and Safety of Ultra Small Dose Decitabine for the Lower Risk MDS Patients With Transfusion Dependent

Myelodysplastic Syndromes

China
Groupe Francophone des Myelodysplasies
Roche Pharma AG

Completed

Erlotinib in Higher Risk Myelodysplastic Syndrome

Myelodysplastic Syndrome

France
Apogenix GmbH

Completed

APG101 in Myelodysplastic Syndrome (APG101 in MDS)

Myelodysplastic Syndrome

Germany

Clinical Trials on Nefrotisk+syndrom

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malaysia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations